260 related articles for article (PubMed ID: 38474142)
41. Targeting E-cadherin expression with small molecules for digestive cancer treatment.
Song Y; Ye M; Zhou J; Wang Z; Zhu X
Am J Transl Res; 2019; 11(7):3932-3944. PubMed ID: 31396310
[TBL] [Abstract][Full Text] [Related]
42. E-Cadherin gene expression in oral cancer: Clinical and prospective data.
López-Verdín S; Martínez-Fierro ML; Garza-Veloz I; Zamora-Perez A; Grajeda-Cruz J; González-González R; Molina-Frechero N; Arocena-Sutz M; Bologna-Molina R
Med Oral Patol Oral Cir Bucal; 2019 Jul; 24(4):e444-e451. PubMed ID: 31256188
[TBL] [Abstract][Full Text] [Related]
43. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
Front Immunol; 2019; 10():1149. PubMed ID: 31178870
[TBL] [Abstract][Full Text] [Related]
44. Personalized medicine: going to the dogs?
Mealey KL; Martinez SE; Villarino NF; Court MH
Hum Genet; 2019 May; 138(5):467-481. PubMed ID: 31032534
[TBL] [Abstract][Full Text] [Related]
45. P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer.
Farzad N; Barati N; Momtazi-Borojeni AA; Yazdani M; Arab A; Razazan A; Shariat S; Mansourian M; Abbasi A; Saberi Z; Badiee A; Jalali SA; Jaafari MR
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):665-673. PubMed ID: 30829072
[TBL] [Abstract][Full Text] [Related]
46. The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxil) exerts anti-tumour effects in vitro independent of cyclooxygenase-2 expression levels.
Hurst EA; Pang LY; Argyle DJ
Vet Comp Oncol; 2019 Jun; 17(2):194-207. PubMed ID: 30767381
[TBL] [Abstract][Full Text] [Related]
47. Oncolytic activity of canine distemper virus in canine mammary tubular adenocarcinoma cells.
Li P; Wang J; Chen G; Zhang X; Lin D; Zhou Y; Yu Y; Liu W; Zhang D
Vet Comp Oncol; 2019 Jun; 17(2):174-183. PubMed ID: 30756476
[TBL] [Abstract][Full Text] [Related]
48. The growing role of precision and personalized medicine for cancer treatment.
Krzyszczyk P; Acevedo A; Davidoff EJ; Timmins LM; Marrero-Berrios I; Patel M; White C; Lowe C; Sherba JJ; Hartmanshenn C; O'Neill KM; Balter ML; Fritz ZR; Androulakis IP; Schloss RS; Yarmush ML
Technology (Singap World Sci); 2018; 6(3-4):79-100. PubMed ID: 30713991
[TBL] [Abstract][Full Text] [Related]
49. Canine Mammary Tumors: Comparison of Classification and Grading Methods in a Survival Study.
Canadas A; França M; Pereira C; Vilaça R; Vilhena H; Tinoco F; Silva MJ; Ribeiro J; Medeiros R; Oliveira P; Dias-Pereira P; Santos M
Vet Pathol; 2019 Mar; 56(2):208-219. PubMed ID: 30381007
[TBL] [Abstract][Full Text] [Related]
50. Current biomarkers of canine mammary tumors.
Kaszak I; Ruszczak A; Kanafa S; Kacprzak K; Król M; Jurka P
Acta Vet Scand; 2018 Oct; 60(1):66. PubMed ID: 30373614
[TBL] [Abstract][Full Text] [Related]
51. Oncolytic Viruses for Canine Cancer Treatment.
Sánchez D; Cesarman-Maus G; Amador-Molina A; Lizano M
Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30373251
[TBL] [Abstract][Full Text] [Related]
52. Malignant canine mammary epithelial cells shed exosomes containing differentially expressed microRNA that regulate oncogenic networks.
Fish EJ; Irizarry KJ; DeInnocentes P; Ellis CJ; Prasad N; Moss AG; Curt Bird R
BMC Cancer; 2018 Aug; 18(1):832. PubMed ID: 30126376
[TBL] [Abstract][Full Text] [Related]
53. Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance.
Nami B; Wang Z
Cancers (Basel); 2018 Aug; 10(8):. PubMed ID: 30126203
[TBL] [Abstract][Full Text] [Related]
54. Molecular Classification of Breast Cancer.
Provenzano E; Ulaner GA; Chin SF
PET Clin; 2018 Jul; 13(3):325-338. PubMed ID: 30100073
[TBL] [Abstract][Full Text] [Related]
55. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Wolff AC; Hammond MEH; Allison KH; Harvey BE; Mangu PB; Bartlett JMS; Bilous M; Ellis IO; Fitzgibbons P; Hanna W; Jenkins RB; Press MF; Spears PA; Vance GH; Viale G; McShane LM; Dowsett M
J Clin Oncol; 2018 Jul; 36(20):2105-2122. PubMed ID: 29846122
[TBL] [Abstract][Full Text] [Related]
56. Cellular Mucins: Targets for Immunotherapy.
Apostolopoulos V; McKenzie IFC
Crit Rev Immunol; 2017; 37(2-6):421-437. PubMed ID: 29773028
[TBL] [Abstract][Full Text] [Related]
57. Immunohistochemical evaluation of bcl-2, ER-alpha, caspase -3, -8, -9, PCNA and Ki-67 expressions in canine mammary carcinomas.
Aydogan A; Ozmen O; Haligur M; Sipahi C; Ileri D; Haligur A
Biotech Histochem; 2018; 93(4):286-292. PubMed ID: 29565181
[TBL] [Abstract][Full Text] [Related]
58. Engineering chimeric antigen receptor-T cells for cancer treatment.
Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
[TBL] [Abstract][Full Text] [Related]
59. PDGFR-α, PDGFR-β, VEGFR-2 and CD117 expression in canine mammary tumours and evaluation of the in vitro effects of toceranib phosphate in neoplastic mammary cell lines.
Gattino F; Maniscalco L; Iussich S; Biasato I; Martano M; Morello E; Gola C; Millán Ruiz Y; Saeki N; Buracco P; Martín de Las Mulas J; De Maria R
Vet Rec; 2018 Aug; 183(7):221. PubMed ID: 29440590
[TBL] [Abstract][Full Text] [Related]
60. Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas.
Hernandez B; Adissu HA; Wei BR; Michael HT; Merlino G; Simpson RM
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
